QurAlis' QRA-244 — An Alternative for Retigabine (Trobalt)?

They expanded the number of candidates and are apparently open for recruitment again. They postponed the completion date to September, unfortunately.

 

Do you happen to know if it is this particular trial?

 

@Matchbox, are you saying Kv7.1 is more important than Kv7.2/3? I read Kv7.1 is expressed in the inner ear.

 

Good question. It looks like it, but I'm not sure.

 

The page reads:

"The study compound will only be administered once during the clinical trial."

And according to QurAlis' ClinicalTrials.gov page, "This study will be a randomized, double-blind, placebo-controlled single ascending dose (SAD) study."

So participating in this study is probably completely useless for tinnitus & hyperacusis anyway.

 

Do you believe Kv7.1 has anything to do with noxacusis? Would XEN1101 be not as useful because it only targets Kv7.2/3?

 

I don't know what to think regarding the specific channels. I think potassium channel openers are potentially useful.

 

Would these potassium channel openers be dangerous to people who already have visual snow?

 

Again, I don't know. What are the side effects from the clinical trials? Have you read them or the transcripts? I would think there's a possibility. You won't ever get a medication that is free of side effects for 100% of the population.

 

Just checked up on this. Phase 1 completes 23/01/2024. 128 enrolled.

 

Good news!